[Clinico-laboratory research on the pharmacodynamic characteristics of Rigevidon].
A contraceptive effect of Rigevidon depends on the drug influence on cyclic secretion of gonadotropic hormones. Rigevidon fails to exert a significant effect on prolactin secretion. The drug withdrawal results in a comparatively rapid restoration (within the first three months) of the generative function.
D001831:Body Temperature / Q000187:drug effects; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology*; D004958:Estradiol / Q000097:blood; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D008597:Menstrual Cycle / Q000187:drug effects; D009644:Norgestrel / Q000494:pharmacology*; D010053:Ovary / Q000187:drug effects; D011374:Progesterone / Q000097:blood; D013997:Time Factors; D014626:Vaginal Smears
D003278:Contraceptives, Oral, Hormonal; D006065:Gonadotropins, Pituitary; D009644:Norgestrel; D004997:Ethinyl Estradiol; D011374:Progesterone; D004958:Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination
Kliniko-laboratornoe issledovanie osobennosteĭ farmakodinamiki rigevidona.